Clinical Trial Update: First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL [Phase 1]

View source ↗

Summary

First-in-human, single-agent study of SAR442257 in relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin lymphoma. The trial is in Phase 1 an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma
• Or Refractory Non-hodgkin Lymphoma

Drugs mentioned

• SAR442257

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1 | Status: ACTIVE_NOT_RECRUITING